Sarcoma | Clinical

Study of Envafolimab +/- Ipilimumab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Will Continue

October 11, 2022

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.